SCHEMBL5162302

SCHEMBL5162302

CCc1cc2c(OC)cc3ccccc3c2n1Cc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G10 O15496 4/20 0.54
PLA2G1B P04054 4/20 0.54
PLA2G2E Q9NZK7 4/20 0.54
PLA2G2D Q9UNK4 4/20 0.54
PLA2G2A P14555 3/20 0.54
PLA2G2F Q9BZM2 3/20 0.45
PLA2G5 P39877 2/20 0.45
MTNR1A P48039 2/20 0.42
MTNR1B P49286 2/20 0.42
KMT2A Q03164 4/20 0.39
MEN1 O00255 2/20 0.39
ATM Q13315 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
ALDH1A1 P00352 1/20 0.39
BRD4 O60885 1/20 0.38
TLR7 Q9NYK1 1/20 0.38
GFER P55789 1/20 0.38
DRD2 P14416 1/20 0.37
DRD4 P21917 1/20 0.37
KCNA3 P22001 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5160095 0.83 PLA2G2A (0.52) PLA2G10PLA2G1BPLA2G2EPLA2G2DPLA2G2A
SCHEMBL14608034 0.82 ALDH1A1 (0.45) PLA2G10PLA2G1BPLA2G2EPLA2G2DPLA2G2A
SCHEMBL5162898 0.80 PLA2G10 (0.55) PLA2G10PLA2G1BPLA2G2EPLA2G2DPLA2G2A
SCHEMBL5160158 0.79 PLA2G10 (0.54) PLA2G10PLA2G1BPLA2G2EPLA2G2DPLA2G2A
SCHEMBL6335034 0.78 PLA2G2A (0.48) PLA2G2AMTNR1AMTNR1BBRD4
SCHEMBL5160134 0.78 KMT2A (0.55) PLA2G10PLA2G1BPLA2G2EPLA2G2DPLA2G2A
SCHEMBL6279125 0.77 MTNR1A (0.44) PLA2G10PLA2G1BPLA2G2EPLA2G2DPLA2G2A
SCHEMBL26473 0.75 MTNR1B (0.67) PLA2G2AMTNR1AMTNR1BKMT2APTGDR2
SCHEMBL14608169 0.74 PLA2G10 (0.41) PLA2G10PLA2G1BPLA2G2EPLA2G2DPLA2G2A
SCHEMBL5530394 0.71 PLA2G2A (1.00) PLA2G10PLA2G1BPLA2G2EPLA2G2DPLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1358156-B1 BENZ(G) INDOLES AND THEIR USE AS SPLA2 INHIBITORS LILLY CO ELI (US) 2007-02-21 EP disclosed
EP-1358156-B1 BENZ(G) INDOLES AND THEIR USE AS SPLA2 INHIBITORS LILLY CO ELI (US) 2007-02-21 EP disclosed
US-6916840-B2 Spla2 inhibitors ELI LILLY AND COMPANY (US) 2005-07-12 US disclosed
US-20040063967-A1 Novel spla2 inhibitors BEIGHT DOUGLAS WADE (US) 2004-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063967-A1 Novel spla2 inhibitors PLA2G12A, SPINT2, PLA2G4A PLA2G10 18/4885PLA2G1B 14/4885PLA2G2E 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.